JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.

Gallipoli, Paolo

View / Open Files

Accepted version (PDF, 172Kb)

Authors

Gallipoli, Paolo

Publication Date

2018-12

Journal Title

Leuk Res

ISSN

0145-2126

Publisher

Elsevier BV

Volume

Pages

71-72

Language

eng

Type

Article

This Version

Physical Medium

Print-Electronic

Metadata

Show full item record

Citation

Gallipoli, P. (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.. Leuk Res, 75 71-72. https://doi.org/10.1016/j.leukres.2018.10.010

Keywords

Humans, Pyrazoles, Antineoplastic Agents, Protein Kinase Inhibitors, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Sponsorship

Medical Research Council (MC_PC_12009)

Wellcome Trust (109967/Z/15/Z)

Identifiers

External DOI: https://doi.org/10.1016/j.leukres.2018.10.010

This record's URL: https://www.repository.cam.ac.uk/handle/1810/286785

Rights

Licence:

http://www.rioxx.net/licenses/all-rights-reserved